Cyclic nucleotide phosphodiesterases

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 5, 2001, Pages 671-680

  Essayan, David M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cyclic AMP; Cyclic GMP; Cyclic nucleotide phosphodiesterase; Immunosuppression; Inflammation

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; AMINOPHYLLINE; ATIZORAM; BENZAFENTRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; FORSKOLIN; MILRINONE; PHOSPHODIESTERASE I INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; ROFLUMILAST; ROLIPRAM; SIGUAZODAN; SILDENAFIL; THEOPHYLLINE; TIBENELAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE; XANTHINE DERIVATIVE; ZAPRINAST; ZARDAVERINE;

BASOPHIL; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME MECHANISM; ENZYME STRUCTURE; EOSINOPHIL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MAST CELL; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 0035188826     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.119555     Document Type: Article

References (142)

1. On the medical history of xanthines and other remedies for asthma: A tribute to HH Salter
2. The properties of an adenine ribonucleotide produced with cellular particles, ATP, Mg++, and epinephrine or glucagon
3. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles
4. The role of cyclic AMP in the cytolytic activity of lymphocytes
5. The role of cyclic 3′,5′ adenosine monophosphate in the specific cytolytic activity of lymphocytes
6. Modulation of inflammation and immunity by cyclic AMP
7. Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity
8. Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues
9. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1.3-disubstituted and 1,3,8-trisubstituted xanthines
10. Cyclic nucleotide phosphodiesterases: Relating structure and function
11. The molecular biology of cyclic nucleotide phosphodiesterases
12. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
13. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
14. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
15. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
16. Cloning and characterization of two splice variants of human phosphodiesterase 11A
17. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
18. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: Identification and differential expression of immunologically distinct forms in the rat brain
19. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
20. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases
21. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
22. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity
23. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions
24. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation
25. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation
26. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain
27. Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)
28. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram
29. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B
30. Recombinant expression of a type IV, cAMP-specific phosphodiesterase: Characterization and structure-function studies of deletion mutants
31. Structure, mechanism, and regulation of mammalian adenylyl cyclase
32. Regulation and role of adenylyl cyclase isoforms
33. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists
34. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors
35. Subcellular localization of rolipramsensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene
36. Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: Selective localization in membrane and cytosolic compartments and differential expression in various brain regions
37. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram
38. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cAMP metabolism in PC12 cells
39. Cyclic nucleotide-dependent protein kinases: Intracellular receptors for cAMP and cGMP action
40. Coordination of cAMP signaling events through PKA anchoring
41. PKA-induced stimulation of ROMK1 channel activity is governed by both tethering and non-tethering domains of an A kinase anchor protein
42. Regulation of Na(+)-K(+)-ATPase by cAMP-dependent protein kinase anchored on membrane via its anchoring protein
43. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein
44. Cyclic GMP-dependent protein kinases: Understanding in vivo functions by gene targeting
45. AKAPs: From structure to function
46. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
47. The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the beta 2-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization
48. Characterization of distinct tethering and intracellular targeting domains in AKAP75, a protein that links cAMP-dependent protein kinase II beta to the cytoskeleton
49. AKAP proteins anchor cAMP-dependent protein kinase to KvLQT1/IsK channel complex
50. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells
51. Signaling pathways for antigen receptor-mediated induction of transcription factor CREB in B lymphocytes
52. Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility
53. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3
54. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
55. Pharmacologic control of histamine release from human basophils induced by platelet-activating factor
56. Preliminary identification and role of phosphodiesterase isozymes in human basophils
57. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function
58. Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation
59. Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE
60. LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments
61. The effects of anti-asthma drugs on mediator release from cultured human mast cells
62. Role of cyclic 3′,5′-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells
63. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study
64. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram
65. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs
66. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
67. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils
68. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression
69. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram
70. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects
71. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation
72. Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4
73. Effect of cyclic AMP-elevating agents on human spontaneous IgE synthesis in vitro
74. Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells
75. Interleukin-4 overcomes the negative influence of cyclic AMP accumulation on antigen receptor stimulated B lymphocytes
76. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro
77. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition
78. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors
79. Identification of cyclic AMP phosphodiesterases 3, 4, and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2
80. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3
81. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes
82. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors
83. Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: A potential novel approach to preventing allograft rejection?
84. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones
85. Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production
86. Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes
87. Regulation of IL-15-stimulated TNF-alpha production by rolipram
88. Rolipram, a type 4 phosphodiesterase (PDE) inhibitor, promotes induction of neoantigen tolerance in murine T cells
89. CD3- and CD28-dependent induction of PDE7 required for T cell activation
90. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages
91. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
92. Interactions between cAMP- and cGMP-dependent protein kinase inhibitors and phosphodiesterase IV inhibitors on arachidonate release from human monocytes
93. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response
94. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
95. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells
96. Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP
97. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells
98. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors
99. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors
100. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs
101. Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages
102. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects
103. Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils
104. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol
105. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes
106. Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: Role of intracellular cyclic AMP levels
107. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators
108. Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4
109. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium
110. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1)
111. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells
112. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4
113. Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist-induced rises in internal calcium in human endothelial cells
114. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation
115. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs
116. Recent advances in antihypertensive therapy
117. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies
118. Phosphodiesterase 5 inhibition: Effects on the coronary vasculature
119. Maintenance of cAMP in non-heart-beating donor lungs reduces ischemiareperfusion injury
120. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
121. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family
122. Oral sildenafil in the treatment of erectile dysfunction
123. Sildenafil (Viagra) and ophthalmology
124. Theophylline for the treatment of bronchial asthma: Present status
125. The role of theophylline in asthma management
126. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs
127. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats
128. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats
129. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4
130. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity
131. Trials of the bronchodilator activity of the isozyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test
132. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma
133. Prevents bronchospasm in asthma of moderate severity
134. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiinflammatory effects in atopic dermatitis
135. Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets
136. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
137. ARIFLO efficacy in a 12-month study of patients with asthma
138. Cilomilast (ARIFLO), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: Results of a 6-month trial
139. Cilomilast (ARIFLO) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6-month trial
140. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
141. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks